Pierre Sabouret
Cardiology — Pitié-Salpêtrière Hospital, France
Pierre Sabouret
LeadR Profile
Cardiology
Subspecialties: Public Health - Hematology - Biostatistics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Pierre SABOURET
Cardiologist
Affiliation : Heart Institute, Cardiology Department, 47-83 boulevard de l’Hôpital, 75013 Paris-FR
Executive Committee Member for education at the European Atherosclerosis Society 2025-2028
President of the National Collège of French Cardiologists (CNCF) 2021-2024
President of the Scientific Committee of CNCF 2018-2021
Senior Investigator in phase II, III, IV clinical studies for the ACTION Group (Sorbonne University) since 2010
Associate Editor at Minerva Cardiology-Angiology
Associate Editor at Archives of Medical Sciences
Associate Editor of Vessel Plus
Associate Editor of Advances in Clinical and Experimental Medicine
Reviewer for Atherosclerosis journal, Eur Heart J Open,Eur J of Preventive Cardiol, EHJCVP, JACC, BMC disorders, Arch Med Sciences.
European Atherosclerosis Society (EAS) Social Media Ambassador
Scientific director of LEN- AXIS TV (French journal and TV providing CME) since 2020. 260 TV sessions with AXIS TV.
Publications pubmed indexed 150 (may 2026)
Organizations
Career arc: 1998 - 2026
Number : 202
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| GLP-1 receptor agonists and SGLT2 inhibitors in cardiovascular practice: insights from a national survey of French cardiologists. glucagon-like peptide 1, sodium-glucose transporter 2 inhibitors, glucagon-like peptide-1 receptor, cardiologists | Arch Med Sci | 2026 | 0 |
| Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions. research design, genes, oligonucleotides, antisense, aortic valve stenosis, apoprotein(a), lipoproteins, cardiovascular diseases, arteries, biomarkers, aortic valve, aortic valve disease, atherosclerosis, therapeutics, lipoprotein(a), apolipoproteins | Rev Cardiovasc Med | 2026 | 0 |
| Toward Precision Cardio-Oncology: Integrating Biomarkers and Cardiac Imaging for Cardiovascular Risk Assessment in Patients With Cancer. risk assessment, neoplasms, biomarkers, therapeutics, cardio-oncology | Oncol Res Treat | 2026 | 0 |
| Beyond the Culprit Lesion and Traditional Risk Factors: New Data on Residual Coronary Risk After Premature Myocardial Infarction. myocardial infarction, cardiovascular diseases, risk factors | Turk Kardiyol Dern Ars | 2026 | 0 |
| Sex-informed interpretation of coronary artery calcium in primary prevention. cardiovascular diseases, arteries, calcium, sex characteristics, sex, primary prevention, enhancer elements, genetic, sex differences | Future Cardiol | 2026 | 0 |
Clinical Studies 6
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI NCT04951856 — injections, myocardial infarction, st elevation myocardial infarction, hydroxymethylglutaryl-coa reductase inhibitors, non-st elevated myocardial infarction, random allocation, injections, subcutaneous | Phase 4 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map